Affiliation:
1. Defence Research and Development Canada (DRDC), Suffield Research Centre, Medicine Hat, Alberta, Canada
Abstract
ABSTRACT
A subunit vaccine candidate was produced from
Brucella suis
145 (biovar 4; expressing both the A antigen of
Brucella abortus
and the M antigen of
Brucella melitensis
). The preparation consisted mostly of polysaccharide (PS; >90% [wt/wt]; both cell-associated PS and exo-PS were combined) and a small amount of protein (1 to 3%) with no apparent nucleic acids. Vaccinated mice were protected (these had a statistically significant reduction in bacterial colonization compared to that of unvaccinated controls) when challenged with representative strains of three
Brucella
species most pathogenic for humans, i.e.,
B. abortus
,
B. melitensis
, and
B. suis
. As little as 1 ng of the vaccine, without added adjuvant, protected mice against
B. suis
145 infection (5 × 10
5
CFU), and a single injection of 1 μg of this subunit vaccine protected mice from
B. suis
145 challenge for at least 14 months. A single immunization induced a serum IgG response to
Brucella
antigens that remained elevated for up to 9 weeks. The use of heat (i.e., boiling-water bath, autoclaving) in the vaccine preparation showed that it was thermostable. This method also ensured safety and security. The vaccine produced was immunogenic and highly protective against multiple strains of
Brucella
and represents a promising candidate for further evaluation.
Publisher
American Society for Microbiology
Subject
Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献